Non-alcoholic fatty liver already affects around 40 percent of the population.
It can lead to liver inflammation (fatty liver hepatitis), liver cirrhosis and liver cancer. The disease is strongly associated with diabetes, obesity or metabolic syndrome, but also with genetic processes and changes in the gut microbiome.
Currently, no drug therapies have been established for the disease. The main goal in the research of non-alcoholic fatty liver is therefore the participation in international clinical trial protocols, as well as the characterization of the natural course and non-invasive staging.